Composition

Affected item:  

Contains 1 ampoule (2 ml) of solution

100 mg contains ethylmethylhydroxypyridine succinate.
Auxiliary substances:sodium metabisulfite (E223), water for injection.

 

Description: Colorless or yellowish transparent liquid.

 

Pharmacotherapeutic group

Means affecting the nervous system.

 

pharmacological properties

Pharmacodynamics

NIKOMEKS is an inhibitor of free radicals, has a membranoprotective, antihypoxic, nootropic, anticonvulsant, anxiolytic and stressprotective effect.

The drug increases the body's resistance to the main damaging factors, oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral blood circulation disorders, intoxication with alcohol and antipsychotic drugs).

Nikomeks improves brain metabolism and blood supply, microcirculation, rheological properties of blood, weakens platelet aggregation. Prevents damage to the membrane of blood cells (erythrocytes and platelets). It has a hypolipidemic effect by reducing the level of total cholesterol and ASLP. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.  

Nikomeks has an antihypoxant, antioxidant and membranoprotective effect. The drug inhibits the processes of lipid peroxidation, reduces the activity of superoxide dismutase, regulates the lipid-protein ratio and the structure of the membrane. Regulates the activity of membrane-related enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), increases the connection of receptor complexes (benzodiazepine, QAYT, acetylcholine) with ligands, structural-functional organization of biomembranes, transport of neurotransmitters and synapse transmission _cc781905-5cde-3194 -bb3b-136bad5cf58d_improves. Nikomex increases the amount of dopamine in the brain. Strengthens compensatory activity of aerobic glycolysis. Hipoksiya şəraitində Krebs siklinin oksidləşdirici proseslərini  sürətləndi-rərək  ATF-in, kreatin fosfatın səviyyəsini  və  mitoxondridə increases energy production, protects the cell membrane.

Nikomeks regulates myocardial electrical activity  and accumulation by improving metabolic processes in the area of ischemia. It reduces the area of necrosis in the myocardium, increases coronary blood supply in the area of ischemia, and prevents complications of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitropreparations.

Nikomeks protects against chronic ischemia, progressive neuropathy of the optic nerve and retinal ganglion cells as a consequence of hypoxia. Improves the functional activity of the retina and optic nerve, increases visual acuity.

Pharmacokinetics

When administered intramuscularly, it is determined in the blood plasma within 4 hours. The time to reach the maximum concentration is T max  0.45-0.5 hours.

Nikomex easily enters organs and tissues and is quickly eliminated from the body.

The drug is mainly excreted in the urine in a glucuronide conjugate, and a small part is excreted unchanged.

 

Instructions for use 

• Brain - acute violation of blood circulation

• Skull - brain trauma and its complications

• Discirculatory encephalopathy

• Vegetative vascular dystonia syndrome

• Mild cognitive impairment due to atherosclerosis

• Neurotic and neurotic states

• Complex therapy of acute myocardial infarction (from the first day)

• Abstinence passing through neuro-like and vegetative-vascular changes of alcoholism

in order to eliminate the syndrome

• Acute intoxication with antipsychotic drugs

• Complex therapy of acute purulent-inflammatory processes of the abdominal cavity

(acute necrotic pancreatitis, peritonitis)

 

Contraindications

Acute liver and kidney failure. Hypersensitivity to the drug. Pregnancy and lactation period, use in children.

 

Method of use and dosage

Nikomex is administered intramuscularly and intravenously in the form of infusion (infusion, drip).

Doses are determined individually.

In the infusion method, the drug is dissolved in 0.9% NaCl solution (200 ml).

Treatment in adults starts from 50-100 mg 1-3 times a day.

The dose can be increased until the therapeutic effect is obtained.

The dosage of the drug is determined according to the disease.

 

Side effects:nausea and dry mouth, drowsiness, allergic reaction, fear, headache, coordination disorder, high and low blood pressure   can be observed.

 

Release form

2 ml solution for injection, in a glass ampoule. 5 ampoules are packed in 2 blisters in a cardboard box.

 

Store condition:

It should be stored at a temperature below 25°С, in its own box, in a dark, dry place and out of the reach of children.
 

Shelf life:3 years.

 

Producer: "Lekhim - Kharkov" JSC, Ukraine.